参考文献：
［1］VUJIYAMA S,SAITOH S,KAWAMURA Y,et al.Portal vein thrombosis in liver cir rhosis:incidence,management,and outcome［J］.BMC Gastmenteml,2017,17（1）:112.
［2］ARGINI C,BERZIGOTTI A.Portal vein thrombosis:The role of imaging in the clinical setting［J］.Dig Liver Dis,2017,49（2）:113-120.
［3］0GREN M,BERGQVIST D,BJORCK M,et al.Portal Vein thrombosis：prevalence,patient Characteristics and Lifetime risk:a population study based on 23796 consecutive autopsies［J］.world J Gastroenterol,2006,12（13）:2115-2119.
［4］ABDEL—RAZIK A, MOUSA N,ELHELALY R,et al. Denovo portal vein thrombosis in liver cirrhosis：risk factors and correlation with the model for endstage liver disease scoring system［J］.Eur J Gastroenterol Hepatol,2015,27（5）:585-592.
［5］MARUYAMA H,OKUGAWA H,TAKAHASHI M,et al.De novo portal vein thrombosis in virus-related cirrhosis：predictive factors and long-term outcomes［J］.Am J GastroenteroZ,2013,108（4）:568-574.
［6］JANSSEN HL,WIJNHOUD A,HAAGSMA EB,et al.Extrahepatic portal vein thrombosis：aetiology and determinants of survival［J］.Gut,2001,49（5）:720-724.
［7］谢渭芬.肝硬化门静脉血栓管理专家共识［J］.中华消化杂志， 2020，40（11）：721-730.
［8］朱铁楠，赵永强.2012 版易栓症诊断中国专家共识解读［J］.临床血液学杂志，2013，26（2）：156-157.(https://www.daowen.com)
［9］HOTOLEANU C.Genetic risk factors in venous thromboembolism［J］.Adv Exp Med Biol,2017,906:253.
［10］TEN KATE MK,VAN DER MEER J.Protein S deficiency:a clinical perspective［J］.Haemophilia,2008,14（6）:1222.
［11］王增智，赵秀清，李杰，等.汉族无诱因肺血栓栓塞症患者天然抗凝蛋白缺陷的发生率及临床特点分析［J］.中国医药，2018，13（8）：1156.
［12］PIER MANNUCCIO MANNUCCI,MASSIMO FRANCHINI.Classic thrombophilic gene variants［J］,Thromb Haemost,2015,114（5）:885.
［13］WYPASEK E1,UNDAS A.Protein C and protein S deficiency-practical diagnostic issues［J］.Adv Clin Exp Med,2013,22（4）:459.
［14］AMR SHAABAN HANAFY,SHERIEF ABD-ELSALAM.Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis［J］.Vascular Pharmacology,2019,113:86-91.
（黎环 林勇 林春 潘晨）